I
Iantrek
Develops technology for minimally invasive microinvasive glaucoma surgery
About Iantrek
iAntrek Medical, accessible at iantrekmed.com, is a pioneering startup in the medical device industry, specifically targeting the ophthalmology sector. The company has developed the CycloPen System, an advanced piece of instrumentation designed for high-fidelity gonio interventions. This system is primarily used in the treatment of glaucoma, a condition characterized by increased pressure in the eye that can lead to vision loss.
Read full description
The CycloPen System allows for controlled and precise cyclodialysis, a surgical procedure that creates a new drainage pathway for the aqueous humor (the fluid in the eye) to reduce intraocular pressure. This device can also be used to insert both viscous and non-viscous materials into the uveoscleral space, which is another pathway for aqueous humor outflow. By reinforcing cyclodialysis, the CycloPen System enhances and ensures durable aqueous outflow, thereby offering a long-term solution for glaucoma patients.
iAntrek Medical primarily serves ophthalmologists and eye care clinics that specialize in glaucoma treatment. The company operates in the medical device market, which is a highly specialized and regulated sector. Their business model revolves around the development, manufacturing, and sale of their proprietary CycloPen System. Revenue is generated through the direct sale of these devices to medical professionals and healthcare institutions.
The company positions itself as a technology-driven entity that opens new horizons in interventional glaucoma treatment. By focusing on innovation and precision, iAntrek Medical aims to improve patient outcomes and provide eye care professionals with cutting-edge tools.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- White Plains, United States
- Employees
- 79
- Open positions
- 7
- Dealroom signal
- 92.9/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Ophthalmology, Medical & Healthcare, Surgery, Eye Diseases, Glaucoma, Non-Invasive medical devices and treatments, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Iantrek.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Apr 2026 | $30M | — | Trinity Capital | ↗ |
| SERIES COther financing | Aug 2025 | $42M | $168M | Sectoral Asset Management · Visionary Ventures · JSD I Radius Special Situations · aMoon Fund | ↗ |
Growth signals
Latest recorded traffic for Iantrek is 1.7K monthly website visits, up 30.8% over the last three months. Iantrek's team grew 33.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
aMoon Fund
U.S. Venture Partners
Sectoral Asset Management
Visionary Ventures
JSD I Radius Special Situations
Civilization Ventures
Trinity Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iantrek on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iantrek’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.